{"created":"2025-01-16T01:53:45.759515+00:00","id":2000268,"links":{},"metadata":{"_buckets":{"deposit":"f7aeb46d-2a07-447c-82b0-92d8f6cd4ce2"},"_deposit":{"created_by":3,"id":"2000268","owner":"3","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"2000268"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:02000268","sets":["7:27:45"]},"author_link":[],"control_number":"2000268","item_10_alternative_title_3":{"attribute_name":"その他（別言語等）のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"β３アドレナリン受容体遮断は、エンドトキシン起因の敗血症性心不全における誘導型一酸化窒素合成酵素を抑制し、心筋代謝を改善する事で生存率を改善する","subitem_alternative_title_language":"ja"}]},"item_10_biblio_info_21":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueNumber":"2","bibliographicPageEnd":"H294","bibliographicPageStart":"H283","bibliographicVolumeNumber":"318","bibliographic_titles":[{"bibliographic_title":"American journal of physiology. Heart and circulatory physiology","bibliographic_titleLang":"en"}]}]},"item_10_date_granted_30":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2020-09-30"}]},"item_10_degree_grantor_32":{"attribute_name":"item_10_degree_grantor_32","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"旭川医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"10107","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10_degree_name_31":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10_description_28":{"attribute_name":"識別番号 その他","attribute_value_mlt":[{"subitem_description":"PMID: 31834837","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10_description_33":{"attribute_name":"item_10_description_33","attribute_value_mlt":[{"subitem_description":"The β3-adrenergic receptor (β3AR) is related to myocardial fatty acid metabolism and its expression has been implicated in heart failure. In this study, we investigated the role of β3AR in sepsis-related myocardial dysfunction using lipopolysaccharide (LPS)-induced endotoxemia as a model of cardiac dysfunction. We placed mice into three treatment groups and treated each with intraperitoneal injections of the β3AR agonist CL316243 (CL group), the β3AR antagonist SR59230A (SR group), or normal saline (NS group). Survival rates were significantly improved in the SR group compared with the other treatment groups. Echocardiography analyses revealed cardiac dysfunction within 6-12 h of LPS injections, but the outcome was significantly better for the SR group. Myocardial ATP was preserved in the SR group but was decreased in the CL-treated mice. Additionally, quantitative PCR analysis revealed that expression levels of genes associated with fatty acid oxidation and glucose metabolism were significantly higher in the SR group. Furthermore, the expression levels of mitochondrial membrane protein complexes were preserved in the SR group. Electron microscope studies showed significant accumulation of lipid droplets in the CL group. Moreover, inducible nitric oxide synthase (iNOS) protein expression and nitric oxide were significantly reduced in the SR group. The in vitro study demonstrated that β3AR has an independent iNOS pathway that does not go through the nuclear factor-κB pathway. These results suggest that blockading β3AR improves impaired energy metabolism in myocardial tissues by suppressing iNOS expression and recovers cardiac function in animals with endotoxin-induced heart failure.NEW & NOTEWORTHY Nitric oxide production through stimulation of β3-adrenergic receptor (β3AR) may improve cardiac function in cases of chronic heart failure. We demonstrated that the blockade of β3AR improved mortality and cardiac function in endotoxin-induced heart failure. We also determined that LPS-induced inducible nitric oxide synthase has a pathway that is independent of nuclear factor-κB, which worsened cardiac metabolism and mortality in the acute phase of sepsis. Treatment with the β3AR antagonist had a favorable effect. Thus, the blockade of β3AR could offer a novel treatment for sepsis-related heart failure.","subitem_description_type":"Abstract"}]},"item_10_dissertation_number_29":{"attribute_name":"dissertation_number","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第551号"}]},"item_10_relation_24":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1152/ajpheart.00108.2019","subitem_relation_type_select":"DOI"}}]},"item_10_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0363-6135","subitem_source_identifier_type":"PISSN"}]},"item_10_version_type_38":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"川口, 哲","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"カワグチ, サトシ","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"Kawaguchi, Satoshi","creatorNameLang":"en","creatorNameType":"Personal"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2025-01-16"}],"filename":"K551 Kawaguchi Satoshi_TD.pdf","filesize":[{"value":"7.7 MB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://asahikawa-med.repo.nii.ac.jp/record/2000268/files/K551 Kawaguchi Satoshi_TD.pdf"},"version_id":"60d82086-51b1-4bd6-8bcc-c2b17178708d"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"cardiac metabolism","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"endotoxin-induced heart failure","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"lipopolysaccharide","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"sepsis","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"β3-adrenergic receptor.","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"β3-Adrenergic receptor blockade reduces mortality in endotoxin-induced heart failure by suppressing induced nitric oxide synthase and saving cardiac metabolism","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"β3-Adrenergic receptor blockade reduces mortality in endotoxin-induced heart failure by suppressing induced nitric oxide synthase and saving cardiac metabolism","subitem_title_language":"en"}]},"item_type_id":"10","owner":"3","path":["45"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2025-01-16"},"publish_date":"2025-01-16","publish_status":"0","recid":"2000268","relation_version_is_last":true,"title":["β3-Adrenergic receptor blockade reduces mortality in endotoxin-induced heart failure by suppressing induced nitric oxide synthase and saving cardiac metabolism"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2025-01-16T02:11:44.241380+00:00"}